Molina Healthcare Reports Steep Earnings Decline for 2025 and Significantly Lower 2026 Guidance
MOH is trading near its 52-week low of $133.4 (3.3% below the low).
Summary
Molina Healthcare reported a substantial decline in 2025 earnings and issued significantly lower guidance for 2026, citing unfavorable retroactive revenue adjustments and underperformance in certain segments.
Key Events · Earnings and Guidance · MOH
-
Q4 & FY 2025 Earnings Miss
Reported Q4 2025 adjusted loss per diluted share of $2.75 and full-year 2025 adjusted EPS of $11.03, a 51% decrease year-over-year.
-
Significantly Lower 2026 Guidance
Introduced full-year 2026 adjusted EPS guidance of at least $5.00, a substantial reduction from 2025 results.
-
Operational Headwinds Cited
2025 results were burdened by $2.00 per share from unfavorable retroactive revenue items; 2026 guidance is burdened by $2.50 per share due to new Medicaid contract implementation and MAPD underperformance.
-
Exit of MAPD Product
The company will exit its traditional Medicare Advantage Part D (MAPD) product, representing approximately $1 billion in annual premium, for 2027 due to underperformance.
Analysis · MOH · Finance
Molina Healthcare's financial results for Q4 and full-year 2025 show a sharp deterioration in profitability, with adjusted EPS falling by over 50% year-over-year. The company also reported a significant negative operating cash flow for 2025. The outlook for 2026 is even more concerning, with adjusted EPS guidance set at less than half of the 2025 figure, burdened by new contract implementation costs and underperforming Medicare Advantage Part D (MAPD) products. The decision to exit the $1 billion MAPD product for 2027 underscores the challenges in this segment. This filing indicates substantial operational headwinds and a significant reset of earnings expectations, likely impacting investor confidence, especially as the stock is currently trading below its 52-week low.
At the time of this filing, MOH was trading at $129.00 on NYSE in the Finance sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $133.40 to $359.97. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.